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ABSTRACT
Glutamate racemase (MurI) catalyses the conversion
of L-glutamate to D-glutamate, an important compo-
nent of the bacterial cell wall. MurI from Escherichia
coli inhibits DNA gyrase in presence of the peptido-
glycan precursor. Amongst the two-glutamate race-
mases found in Bacillus subtilis, only one inhibits
gyrase, in absence of the precursor. Mycobacterium
tuberculosis has a single gene encoding glutamate
racemase. Action of M.tuberculosis MurI on DNA
gyrase activity has been examined and its mode of
action elucidated. We demonstrate that mycobacte-
rial MurI inhibits DNA gyrase activity, in addition to
its precursor independent racemization function.
The inhibition is not species-specific as E.coli gyrase
is also inhibited but is enzyme-specific as topoiso-
merase I activity remains unaltered. The mechanism
of inhibition is different from other well-known
gyrase inhibitors. MurI binds to GyrA subunit of the
enzyme leading to a decrease in DNA-binding of the
holoenzyme. The sequestration of the gyrase by MurI
results in inhibition of all reactions catalysed by DNA
gyrase. MurI is thus not a typical potent inhibitor
of DNA gyrase and instead its role could be in
modulation of the gyrase activity.
INTRODUCTION
Topoisomerases are essential enzymes, responsible for main-
tenance of the level of supercoiling of DNA in cells. DNA
gyrase is unique amongst all topoisomerases in its ability to
catalyze negative supercoiling of DNA in an ATP dependent
fashion (1–3). Besides supercoiling, the enzyme catalyzes
catenation/decatenation and knotting/unknotting reactions
in vitro (4,5). It is also known to relax negatively supercoiled
DNA in absence of ATP (6). The functional holoenzyme is a
heterotetramer (A2B2) comprising of two GyrA and GyrB
subunits (7,8).
DNA gyrase is an indispensable enzyme in prokaryotes and
is a proven target for diverse classes of antibacterial agents.
Mechanistically, gyrase inhibitors have been classified
mainly into two broad categories. The first category includes
coumarins and cyclothialidines that inhibit ATP hydrolysis
catalysed by DNA gyrase. These antibiotics bind to GyrB
at a region overlapping to ATP binding site, thus preventing
ATP binding. As a result, they inhibit only the supercoiling
activity of the enzyme with no effect on the relaxation activ-
ity (9,10). The second class includes the synthetic quinolones,
which function as gyrase poisons, by stabilizing enzyme–
DNA covalent intermediates (9,10). The protein–DNA
adducts hinder the progress of replication and transcription
complexes (11,12). They also lead to widespread chromo-
some fragmentation due to the release of DNA ends from
the ternary complexes, resulting in rapid quinolone-mediated
cell death (13). In addition, proteinaceous toxins such as ribo-
somally synthesized peptide antibiotic, microcin B17 (14),
ParE from RK2 plasmid (15) and CcdB encoded by F plasmid
(16) inhibit gyrase by arresting the enzyme–DNA covalent
intermediates, leading to the accumulation of double-strand
breaks, upon removal of the protein constraints. New
inhibitors of DNA gyrase have been reported recently.
These proteins appear to inhibit DNA gyrase in a manner dis-
tinct from the other two classes of inhibitors. For example,
GyrI from Escherichia coli (17,18), MfpA from Mycobac-
terium sp. (19,20) inhibit DNA gyrase by interfering with
gyrase–DNA interaction.
Glutamate racemase (MurI) catalyses the conversion of
L-glutamate to D-glutamate, an essential component of the
peptidoglycan. Besides racemization activity, E.coli MurI
possesses an additional DNA gyrase inhibitory function.
The inhibition of DNA gyrase requires the presence of
peptidoglycan precursor (21). Studies with Bacillus subtilis
revealed that it possesses two genes encoding glutamate
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racemases, the poly-gamma-glutamate synthesis-linking Glr
enzyme and YrpC (22,23). Only the YrpC (MurI) isozyme,
but not the Glr, negatively influences the activity of DNA
gyrase, that too in the absence of the precursor (24).
Mycobacterium tuberculosis genome sequence revealed
the presence of a single gene for glutamate racemase. Further,
mycobacterial DNA gyrase shows distinctive features with
respect to quinolone susceptibility and resistance to the action
of toxins like CcdB and microcin B17 (25–27). Therefore,
in this study, we have examined the effect of glutamate
racemase from M.tuberculosis on DNA gyrase activity and
elucidate its mechanism of action.
MATERIALS AND METHODS
Bacterial strains and plasmids
E.coli strains DH5a and BL26(DE3) were used for cloning
and overexpression of mycobacterial MurI respectively.
Genomic DNA from M.tuberculosis H37Ra was isolated by
the method described earlier (28). The murI gene was cloned
in pET11d vector. pBR322, pUC18 plasmids were used for
the biochemical assays.
Enzyme and substrate preparation
E.coli DNA gyrase subunits, GyrA and GyrB were purified as
described previously (29). Mycobacterium smegmatis DNA
gyrase was purified as described previously (30). Specific
activity of purified DNA gyrase was defined to be 1 U as
the amount of the enzyme required to supercoil 300 ng of
relaxed pUC18 DNA at 37C in 30 min. Supercoiled
pUC18 and pBR322 were prepared by standard DNA puri-
fication protocols (31). M.smegmatis topoisomerase I and
relaxed pUC18 were prepared as described in (32). E.coli
topoisomerase I was purified as described previously (33).
Cloning of murI
The murI gene was PCR amplified using M.tuberculosis
H37Ra genomic DNA as a template and primers (forward pri-
mer 50-GAAGTCATGAATTCGCCGTTG) and (reverse pri-
mer 50-AAGATCTCTTCCATGGCCTAATG) containing
RcaI and BglII sites, respectively. The amplification reaction
was carried out with Pfu DNA polymerase, RcaI and BglII
digested PCR product was ligated to NcoI-BamHI cut
pET11d vector.
Expression and purification of MurI
The recombinant mycobacterial MurI was overexpressed
from pET11d construct in E.coli BL26 (DE3) strain. Cells
were harvested and resuspended in a buffer containing
50 mM Tris–HCl pH 8.0, 1 mM DL-glutamic acid, 0.1 mM
phenylmethyl-sulfonyl fluoride, 0.5 mM MgCl2 and disrupted
by sonication. The extract was centrifuged at 20 000 g for
30 min at 4C (S20 fraction). The S20 pellet fraction
containing MurI was subjected to 12% denaturing PAGE
(SDS–PAGE). The band corresponding to the overexpressed
protein was excised and eluted from the gel using a Bio-
Rad electroelutor. The eluted protein was then subjected
to acetone-precipitation to remove SDS, denatured in
buffer containing 50 mM Tris–HCl pH 8.0, 0.2%
2-mercaptoethanol, 0.1 mM phenyl methane sulfonyl fluoride
and 6 M urea. Subsequently the protein was renatured by
stepwise dialysis against buffer containing 4, 2 and 1 M
urea, respectively. Finally, the purified protein was dialyzed
against the same buffer lacking urea.
Racemization activity
The racemization activity of the purified glutamate racemase
was assessed as described previously (34). Purified MurI
samples were incubated in presence of D-glutamate and
then rapidly heated to inactivate the enzyme and assayed
for L-glutamate using NAD+/L-glutamate dehydrogenase
(GDH). Varying concentrations (1 and 2 mM) of MurI were
incubated with 10 mM D-glutamate in a buffer containing
100 mM Tris–HCl pH 8.0, 2 mM DTT at 37C for 30 min.
Samples were then heated at 95C for 15 min. Denatured
protein was removed by centrifugation for 10 min at
14 000 r.p.m. The L-glutamate formed was then measured
by adding 5 mM of NAD+ and 10 U of GDH. Increase in
absorbance at 340 nm was monitored for 6 min at 25C
using Beckman DU640 UV/vis spectrophotometer. One
aliquot of purified MurI sample (2 mM) was treated with
400 mM methyl methanethiosulfonate (MMTS, cysteine
modifying agent) at 37C for 30 min, dialyzed and then
assessed for its racemization activity.
DNA supercoiling, relaxation and
decatenation reactions
Supercoiling assays were carried out at 37C with 300 ng of
relaxed pUC18 and 10 nM DNA gyrase from either E.coli
or M.smegmatis, in supercoiling buffer [35 mM Tris–HCl
pH 7.5, 5 mM MgCl2, 25 mM potassium glutamate, 2 mM
spermidine, 2 mM ATP, 50 mg/l BSA and 90 mg/l yeast
tRNA in 5% (v/v) glycerol]. Relaxation assays were carried
out with 75 and 150 nM of E.coli enzyme using supercoiled
pBR322 as the substrate in the supercoiling buffer devoid of
ATP. The reactions were carried out either in presence of
MurI or BSA (control) for 60 min at 37C and terminated
with 0.6% SDS. Decatenation reactions were carried out
with 300 ng kinetoplast DNA and 100 nM enzyme in super-
coiling buffer containing 10 mM MgCl2, at 37
C for 60 min.
Relaxation assays with topoisomerase I were carried out in
buffer containing 20 mM Tris–HCl pH 7.4, 40 mM NaCl,
and 5 mM MgCl2. 20 nM of either E.coli or M.smegmatis
topoisomerase I were incubated with supercoiled pUC18
DNA either in presence of MurI or BSA. The reactions
were carried out at 37C for 60 min and stopped with 0.6%
SDS. The assay mixtures were resolved on 1% agarose gel
in 40 mM Tris–actetate buffer containing 1 mM EDTA.
Electrophoretic mobility shift assay
Assays were carried out using a 240 bp DNA fragment
encompassing the strong gyrase site (SGS) from pBR322
(35). The DNA fragment was PCR amplified with the end
labeled forward primer. End-labeling was performed with
[g-32P]ATP (3000 Ci/mmol) and T4 polynucleotide kinase.
In order to assess the effect of MurI on gyrase–DNA non-
covalent complex, labeled DNA (1 · 109 M) was incubated
with 100 nM of DNA gyrase either in absence or presence of
different concentrations of MurI for 30 min at 4C followed
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by electrophoresis on 4% native polyacrylamide gel in
45 mM Tris–borate buffer containing 5 mM MgCl2 at 4
C.
For assessing gyrase–DNA covalent complex, the reactions
were carried out with 40 nM DNA gyrase and in presence
of 30 mg/ml ciprofloxacin at 30C. One of these reaction
mix was treated with 0.2% SDS followed by proteinase K
(90 mg/ml) digestion for 30 min. The samples were elec-
trophoresed on 4% native polyacrylamide gel in 45 mM
Tris–borate buffer at 25C. The free DNA and bound
complexes were then quantitated using a phosphorimager.
Cleavage reactions
DNA cleavage assays were carried out in the supercoiling
buffer with supercoiled pBR322 substrate for 30 min at
30C and the gyrase–DNA complex was trapped by adding
0.2% SDS followed by proteinase K (90 mg/ml) digestion
for 30 min. In case of drug-induced cleavage reactions, cipro-
floxacin (30 mg/ml) was included in the assay. The reaction
mixtures were then resolved on 1% agarose gel. Cleavage
reactions using radiolabelled DNA substrate (240 bp SGS)
were performed in a similar fashion. The reaction buffer
contained 5 mM Ca2+ ions instead of Mg2+ ions, while
monitoring the calcium-induced cleavage. The reaction
products were resolved on 8% denaturing polyacrylamide
gel (urea-PAGE). The substrate and cleaved DNA products
were then quantitated using phosphorimager.
ATPase activity measurements
The ATPase reactions were carried out in supercoiling buffer
containing 2 mM ATP, 10 mg ml1 DNA (240 bp from
pBR322) and 0.02 mCi of [g-32P]ATP (3000 Ci/mmol). The
DNA-stimulated ATPase activity was monitored with
40 nM DNA gyrase either in absence or presence of varying
amounts of MurI. To assess the intrinsic ATPase activity,
1.4 mM GyrB was used and GyrA as well as DNA were omit-
ted from the assay mixture. The assays were terminated
by adding equal volume of chloroform. The aqueous layer
(1.0 ml) was resolved on polyethyleneimine-cellulose thin
layer chromatography with 1.2 M LiCl, and 0.1 mM
EDTA. The spots corresponding to ATP and Pi were
quantitated using a phosphorimager.
Far-western analysis
Thirty-four picomoles each of MurI and KpnI Restriction
endonuclease (used as a negative control) were resolved in
12% SDS–polyacrylamide gel and then transferred onto
nitrocellulose membrane. The proteins were then allowed to
refold on the membrane followed by blocking with buffer
containing 10 mM Tris–HCl pH 8.0, 100 mM NaCl, 1 mM
EDTA, 2% (w/v) BSA. The membrane was then incubated
with 200 pmol of either mycobacterial GyrA or GyrB
subunits individually, washed three times with phosphate-
buffered saline (137 mM NaCl, 2.7 mM KCl, 10 mM
Na2HPO4, 2 mM KH2PO4) containing 0.1% Tween-
20 [PBST]. The membrane was then incubated with either
anti-GyrA rabbit IgG in case of GyrA or anti-GyrB rabbit
IgG at 1:10 000 dilutions followed by three washes with
PBST. The membrane was incubated with secondary
peroxidase-conjugated anti-rabbit antibody at 1:20 000
dilution. ECLplus (Amersham) was used to detect the
bound secondary antibody.
Surface plasmon resonance
E.coli GyrA was immobilized on a CM5 sensor surface via
amine-coupling in acetate buffer (pH 3.0). The surface was
blocked with ethanolamine hydrochloride. The interaction
was assessed in a buffer containing 35 mM Tris–HCl
pH8.0, 1 mM EDTA, 0.05% Tween-20, 100 mM NaCl.
Varying amounts of MurI were passed over the immobilized
GyrA and the subsequent changes in the resonance units were
recorded in a BIAcore 2000 system (Pharmacia). All the
proteins were dialyzed against the buffer (35 mM Tris–HCl
pH 8.0, 1 mM EDTA) prior to the experiment. 10 mM
NaOH was used for surface regeneration.
RESULTS
Purification and racemization activity of purified MurI
M.tuberculosis MurI was overexpressed in E.coli and purified
from the inclusion bodies as described in the Materials and
Methods section (Figure 1A). The authenticity of the protein
was verified by tryptic mass fingerprinting analysis (data not
shown). MALDI-TOF analysis revealed the molecular mass
of the purified protein to be 28 796 Da (Figure 1B). The
racemization activity was assessed by monitoring the
absorbance of NADH at 340 nm. For this, MurI was initially
incubated in presence of D-glutamate. L-Glutamate formed
as a result of MurI racemase activity was measured by
adding NAD+ and GDH. GDH-mediated conversion from
L-glutamate to a-ketoglutarate led to the reduction of
NAD+ to NADH. As shown in Figure 1C, the samples incu-
bated with MurI, showed a significant increase in OD at
340 nm with time in a dose-dependent manner. The reaction
with L-glutamate as a substrate served as a positive control
while the reaction in presence of BSA and D-glutamate served
as a negative control. Glutamate racemases are known to
employ two active-site cysteine residues as acid/base cata-
lysts during the interconversion of glutamate enantiomers
(36). MMTS was used to modify the cysteine residues of
M.tuberculosis MurI. MMTS-treated MurI was compromised
in its racemization function revealing the importance of cys-
teine residues in catalysis (Figure 1C). The racemase activity
of the enzyme was also monitored by circular dichroism spec-
tra at 204 nm (data not shown). The results showed that
M.tuberculosis MurI racemization activity does not require
any peptidoglycan precursor, similar to B.subtilis glutamate
racemases (22,23). As with other glutamate racemases, the
activity is also independent of cofactor requirement.
MurI inhibits DNA gyrase activity
In order to test the effect of MurI on supercoiling activity,
M.smegmatis DNA gyrase was preincubated with MurI for
15 min on ice prior to the addition of DNA substrate (relaxed
pUC18) as described in the Materials and Methods section.
The results presented in Figure 2A show that MurI inhibits
supercoiling activity of mycobacterial DNA gyrase. When
its effect on E.coli DNA gyrase was tested, mycobacterial
MurI was observed to inhibit even the E.coli enzyme
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(Figure 2B). The inhibition of DNA gyrase by MurI is thus
not species-specific in contrast to other proteinaceous
inhibitors such as CcdB, microcin B17 (25).
Apart from the supercoiling reaction, DNA gyrase is
known to catalyze other reactions in vitro, namely ATP-
independent relaxation and decatenation reactions. To ana-
lyze the effect of MurI on gyrase-catalyzed relaxation,
DNA gyrase was preincubated with MurI prior to the addition
of supercoiled pBR322 DNA substrate. As shown in
Figure 2C, MurI inhibited the relaxation activity as well.
To monitor its effect on the decatenation activity of DNA
gyrase, the reactions were carried out using the catenated
kinetoplast DNA as substrate. From the data presented in
Figure 2D, it is evident that MurI inhibited decatenation
activity of DNA gyrase as well. Since all the three catalytic
activities of DNA gyrase are inhibited by M.tuberculosis
MurI, a step common to all these processes is likely to be
the target for MurI action.
MurI has no effect on the topoisomerase I activity
Bacterial topoisomerase I relaxes negatively supercoiled
DNA in an ATP-independent manner. In order to assess the
effect of MurI on the relaxation activity of topoisomerase I,
both M.smegmatis as well as E.coli topoisomerase I were
preincubated with MurI and then supercoiled pUC18 DNA
substrate was added for the relaxation assays as described
in the Materials and Methods section. As shown in
Figure 2E, the topoisomerase I-mediated relaxation reactions
were not inhibited in presence of MurI. Therefore, MurI
appears to be a specific inhibitor of DNA gyrase.
Probing the mechanism of inhibition
The reaction cycle of DNA gyrase involves a series of coor-
dinated steps (2,3). After initial wrapping of DNA around the
A2B2 complex, cleavage of the G segment DNA in both the
strands results in the formation of a DNA–protein covalent
complex. Cleavage reaction is followed by the passage of
an intact duplex T segment DNA through the double-stranded
break. Religation of the broken ends of DNA after the strand
passage results in the introduction of two negative supercoils.
Hydrolysis of ATP is required to reset the reaction cycle for
catalytic enzyme turnover (3). Inhibitors for DNA gyrase,
thus, could potentially interfere at any one of the steps in
the gyrase reaction cycle to arrest the chain of events.
Figure 1. (A) Expression profile of MurI, M: protein molecular weight marker, lane 1: BL26 cell extract harbouring vector pET11d, lane 2: BL26 cell
extract harbouring pET11d-murI construct, induced with 0.3 mM IPTG, lane 3: purified MurI; (B) molecular weight of M.tuberculosis MurI determined by
MALDI-TOF analysis, (C): Racemization activity of MurI. The assay was carried out as described in Materials and Methods section. Reduction of NAD to
NADH during the course of the reaction was monitored by a measuring absorbance at 340 nm. &: reaction with 1 mM BSA, !: reaction with 1 mM MurI and: reaction with 2 mM MurI, : reaction with MMTS treated 2 mM MurI, ~: in presence of 10 mM L-glutamate substrate.
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Effect of MurI on cleavage reaction
The quinolone class of DNA gyrase inhibitors (e.g. nalidixic
acid and ciprofloxacin) inhibit both the supercoiling and
relaxation reactions of DNA gyrase. They act by interfering
with the rejoining of double-stranded breaks in DNA and
promote the rate of double-stranded DNA cleavage by
DNA gyrase (10). In order to test the effect of mycobacterial
MurI at the cleavage step, DNA gyrase was preincubated with
MurI and the cleavage assays were performed both with the
supercoiled plasmid DNA as well as the radiolabelled linear
DNA substrates. In Figure 3, effect of MurI on DNA gyrase-
mediated cleavage has been summarized. Unlike ciprofloxa-
cin, MurI did not stimulate DNA gyrase-mediated cleavage
on its own (Figure 3A, compare lanes 4 and 6). Ciprofloxacin
is known to arrest DNA gyrase at the cleavage step. SDS and
proteinase K treatment removes the covalently attached
protein and cleaved DNA fragment can be visualized on the
gel. The extent of ciprofloxacin-induced cleavage on a super-
coiled plasmid DNA substrate was monitored either in
absence or presence of MurI. The drug-induced DNA cleav-
age was reduced in presence of MurI (Figure 3A, lanes 6–8).
MurI also abrogated the cleavage even on a linear DNA sub-
strate, in a dose-dependent manner (Figure 3B). Calcium
(Ca2+) ions inhibit the religation and known to stimulate
DNA cleavage activity of the enzyme (37). MurI exhibited
a similar inhibitory effect on calcium-induced cleavage
Figure 2. Effect of MurI on activities of topoisomerases: Inhibition of DNA gyrase activities by MurI (A–D). Effect on supercoiling activities of
(A) mycobacterial DNA gyrase and (B) E.coli DNA gyrase respectively. 10 nM DNA gyrase used for the supercoiling reaction; lane 1: relaxed pUC18, lane
2: gyrase in presence of 1 mM BSA, lane 3: gyrase in presence of 1 mM MurI; (C) Relaxation activity. Lane 1: supercoiled pBR322, lanes 2 and 4: 75 and 150 nM
E.coli DNA gyrase in presence of 1 mM BSA respectively; lanes 3 and 5: gyrase in presence of 0.5 and 1 mM MurI respectively; (D) Decatenation activity.
100 nM E.coli DNA gyrase used for the reactions, lane 1: kinetoplast DNA, lane 2: DNA gyrase and 1 mM BSA, lanes 3 and 4: DNA gyrase in presence of
0.5 and 1 mM MurI respectively. (E) Effect on topoisomerase I activity. 20 nM of M.smegmatis and E.coli topoisomerase I were used for the relaxation assays,
lane 1: supercoiled pUC18; lane 2: M.smegmatis topoisomerase I and 1 mM BSA; lane 3: M.smegmatis topoisomerase I with 1 mM MurI; lane 4: E.coli
topoisomerase I and 1 mM BSA; lane 5: E.coli topoisomerase I and 1 mM MurI. S and R represent supercoiled and relaxed plasmid DNA, kN: kinetoplast, kDNA
network, BN: broken network, RM: released minicircles. All the assays were repeated at least thrice. The representative figures have been presented.
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reaction (Figure 3C). From these observations, we conclude
that MurI inhibits DNA gyrase by interfering with the DNA
cleavage reaction or a step preceding it.
Effect of MurI on DNA-binding
Electrophoretic mobility shift assays (EMSAs) were
employed to assess the effect of MurI on gyrase–DNA
interaction. To monitor the effect of MurI on both the non-
covalent and covalent gyrase–DNA complex formation,
reactions were performed as described, either in absence or
presence of ciprofloxacin and DNA gyrase was preincubated
with MurI prior to the addition of DNA. As shown in
Figure 4A, the amount of retarded gyrase–DNA non-covalent
complex on the polyacrylamide gel was significantly reduced
in presence of MurI, with concomitant increase in the free
DNA species. MurI inhibited the formation of non-covalent
enzyme–DNA complex in a dose-dependent manner.
Similarly, the covalent gyrase–DNA complex formation
was hindered by MurI (Figure 4B). From these results, it
appears that by preventing gyrase–DNA interactions,
M.tuberculosis MurI inhibits all the catalytic reactions of
DNA gyrase.
Effect of MurI on ATPase activity
GyrB subunit of DNA gyrase exhibits intrinsic ATPase
activity, which is further enhanced in presence of GyrA and
DNA (38,39). Coumarins and cyclothialidines inhibit super-
coiling activity of the enzyme by interfering with ATPase
activity (intrinsic as well as DNA-stimulated). If DNA-
binding by gyrase is indeed the target of MurI action, the
Figure 3. Effect of MurI on DNA gyrase mediated cleavage reaction: (A) cleavage reactions with supercoiled pBR322 substrate, 50 nM E.coli DNA gyrase used;
lane 1: linear substrate, lane 2: supercoiled substrate, lanes 3 and 6: DNA gyrase, lanes 4 and 7: gyrase in presence of 1 mM MurI, lanes 5 and 8: gyrase in
presence of 1 mM BSA. Ciprofloxacin (30 mg/ml) added in the lanes 6–8; (B) cleavage with linear radiolabelled DNA (SGS). 100 nM E.coli DNA gyrase used;
lane 1: 240 bp SGS, lane 2: DNA gyrase, lane 3: gyrase in presence of 2 mM BSA, lanes 4–7: gyrase in presence of increasing concentrations of MurI.
Ciprofloxacin (30 mg/ml) added in all the lanes. The bar diagrams show the quantitative representations of the % cleavage observed in each lane; (C) cleavage
reactions in presence of calcium ions; lane 1: 240 bp SGS lane 2: DNA gyrase, lane 3: gyrase in presence of 1 mM MurI, lane 4: gyrase in presence of 1 mM BSA.
Mg2+ ions omitted and 5 mM Ca2+ ions added in the reactions. A quantitative representation is shown in the form of bar diagram adjacent to the figure.
A representative set of data is presented based on several sets of experiments.
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DNA-stimulated ATPase activity of the enzyme would be
affected while its intrinsic activity would be unaltered.
Reactions were carried out with DNA gyrase holoenzyme
in presence of linear DNA substrate as described in the
Materials and Methods section. As shown in Figure 5A,
MurI inhibited the DNA-stimulated ATPase activity of
DNA gyrase. To test the effect of MurI on intrinsic ATPase
activity, reactions were carried out with prior incubation of
MurI and only GyrB subunit. MurI had no effect on intrinsic
ATPase activity of the enzyme, in contrast to the pattern
observed with novobiocin (Figure 5B). Together, these data
demonstrate that the MurI mode of inhibition is distinct
from that of the ATPase inhibitors. These results also confirm
that the inhibition of gyrase by MurI is at the step of
DNA-binding.
MurI interacts with GyrA subunit of DNA gyrase
To investigate whether MurI-mediated inhibition is mediated
by direct interaction between the two proteins, two experi-
mental approaches were employed. In the far-western
analysis presented in Figure 6A, upon co-incubation of
immobilized MurI on the membrane with GyrA subunit, we
detected a signal for GyrA at the position of MurI on the
membrane. Similar analysis with GyrB subunit did not give
any positive signal. In order to verify further the direct
interaction, surface plasmon resonance reftractrometric
(SPR) studies were performed. SPR experiments also
revealed a direct interaction between MurI and GyrA subunit
of DNA gyrase, with an increase of 60–70 RU upon binding
of MurI to immobilized GyrA (Figure 6B). The physical
interaction between MurI and DNA gyrase is therefore
independent of the presence of GyrB subunit, DNA and ATP.
DISCUSSION
Mycobacterial glutamate racemase exhibits a dual role like its
E.coli homologue. However, unlike the E.coli enzyme,
mycobacterial MurI inhibits DNA gyrase in a precursor inde-
pendent manner. In this respect, it is similar to the B.subtilis
glutamate racemase, which affects DNA gyrase activity in
absence of any precursor. Previous studies with E.coli and
B.subtilis enzymes have not addressed the mechanism of
inhibition of gyrase by glutamate racemase (21,24). Here,
we demonstrate that the inhibition of gyrase by MurI is not
species-specific. We have then investigated the mechanism
of MurI-mediated inhibition of DNA gyrase. It binds to
Figure 4. Effect of MurI on gyrase–DNA interaction: (A) Effect of MurI on non-covalent complex formation, EMSAs carried out with 100 nM E.coli DNA
gyrase and radiolabelled 240 bp SGS at 4C; lane1: free SGS, lane 2: DNA gyrase, lane 3: gyrase in presence of 1 mM BSA, lane 4–6: gyrase in presence of
increasing concentrations of MurI. (B) Effect on gyrase–DNA covalent complex, 40 nM DNA gyrase incubated with radiolabelled SGS in presence of
ciprofloxacin (30 mg/ml) at 30C to arrest at the cleavage step and covalent enzyme–DNA complexes resolved on 4% native polyacrylamide gel; lane 1: free
SGS, lane 2: DNA gyrase, lane 3: gyrase in presence of 1 mM BSA, lane 4: DNA gyrase in presence of 1 mM MurI, lane 5: gyrase–DNA covalent complex after
proteinase K treatment; CD: cleaved DNA released after proteinase K treatment. All the assays were repeated at least thrice. The representative figures are
shown.
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GyrA subunit and this interaction prevents gyrase from
accessing the DNA substrate, thereby inhibiting all its
catalytic reactions.
DNA gyrase is responsible for the maintenance of steady-
state levels of negative supercoiling that is essential for
chromosome condensation, transcription initiation and
enzyme complex movement during replication and transcrip-
tion. By virtue of being an essential enzyme, it is an ideal
target for different classes of inhibitors. Amongst a large
repertoire of the gyrase inhibitors, coumarins and quinolones
Figure 5. Effect of MurI on ATPase activity: (A) DNA-stimulated ATPase activity. Reactions were performed with 40 nM M.smegmatis DNA gyrase and
10 mg ml1 DNA (240 bp SGS from pBR322), lane 1: gyrase, lanes 2 and 3:gyrase in presence of 0.5 and 1 mM MurI respectively, lane 4: gyrase in presence of
1 mg/ml novobiocin, (B) Intrinsic ATPase activity. Reactions were performed with 1.4 mM E.coli GyrB subunit. DNA and GyrA were omitted; lane 1: GyrB,
lanes 2 and 3: GyrB in presence of 0.5 and 1 mM MurI respectively, lane 4: GyrB in presence of 1 mg/ml novobiocin. 2 mM ATP present in all the reactions. The
average of three independent experiments is depicted graphically.
Figure 6. Interaction between MurI and DNA gyrase: (A) Far-western analysis. 34 picomoles of MurI and KpnI restriction endonuclease immobilized on
nitrocellulose membrane and then incubated with 3 mM of either mycobacterial GyrA or GyrB subunits and then probed with polyclonal antibodies raised against
the mycobacterial DNA gyrase subunits. (lanes 1 and 2): gel stained with coomasie brilliant blue dye, showing the presence of KpnI (K) and MurI (M); (lanes 3
and 4): the nitrocellulose membrane with immobilized KpnI and MurI probed with anti-GyrA (a-GyrA) antibodies after incubation with GyrA, (lanes 5 and 6):
the nitrocellulose membrane with immobilized KpnI and MurI probed with anti-GyrB (a-GyrB) antibodies after incubation with GyrB, (B) Surface plasmon
resonance refractometry. Interaction was assessed in a buffer containing 35 mM Tris–HCl pH 8.0, 1 mM EDTA, 0.05% Tween-20, and 100 mM NaCl. (—) MurI
passed over E.coli GyrA immobilized on CM5 sensor surface, (.......) non-specific control.
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have been studied extensively with respect to their mecha-
nism of action (9,10). A noteworthy point is that new
inhibitors with different mechanism of action are often
discovered for DNA gyrase. Recently, a new class of antibi-
otics with an aminocoumarin moiety in its structure has been
reported to inhibit gyrase in a mode distinct from the other
known coumarins. Simocyclinone D8 inhibits an early step
in gyrase catalytic cycle by preventing DNA-binding by the
enzyme (40). Several proteinaceous inhibitors of DNA
gyrase, discovered so far, could be categorized into two
major groups. The first category includes the toxins like
CcdB, microcin B17, ParE, which are encoded by the selfish
plasmids to ensure their stable maintenance inside the cell
(14–16). These toxins act as gyrase poisons and their mode
of inhibition is akin to that of quinolones but not identical
in all the details. The second group of inhibitors includes
the chromosomally encoded inhibitors such as GyrI, MfpA
and plasmid encoded Qnr. The quinolone resistance protein,
Qnr, discovered from a clinical isolate of Klebsiella pnemo-
niae, binds gyrase holoenzyme thereby altering its DNA-
binding property (41–43). Based on the crystal structure of
MfpA, it is considered to be a DNA mimic, sequestering
gyrase away from DNA (20). GyrI, an endogenous DNA
gyrase inhibitor from E.coli binds to the holoenzyme and
hinders the DNA-binding (18). None of these proteins are
cytotoxic as their mode of inhibition is to prevent DNA
gyrase from binding to DNA. Cytotoxicity usually arises
due to accumulation of double-strand breaks in the genome.
Bacterial cells tolerate some reduction of gyrase activity,
whereas only few double-strand breaks in the genome could
be lethal (44). In this context, amongst all the inhibitors of
DNA gyrase studied so far, quinolones, which form toxic
lesions, are the only commercially successful chemical
entities.
From the present studies, it is clear that MurI mode of
action resembles the other chromosomally encoded gyrase
inhibitors. These inhibitors essentially influence the enzyme
activity by sequestering the enzyme away from DNA. A
comparative analysis of these proteinaceous inhibitors does
not reveal a common motif or structural fold, which might
be involved in their ability to inhibit DNA gyrase. Thus, at
present, it appears that they belong to a group of very dis-
parate proteins having a similar function as far as gyrase
inhibition is concerned.
Apparently, presence of such endogenous inhibitors of an
essential enzyme appears to be a severe burden for the cell.
The intracellular optimal activity of DNA gyrase is very
crucial for cell survival. These endogenous gyrase inhibitory
proteins might be playing a role in regulating DNA gyrase
activity. For example, in case of thioredoxins (TrxA and
TrxC) from Rhodobacter sp., a change in oxygen tension
influences their redox state, resulting in altered gyrase
activity which in turn infuences the expression of puf and
puc operon (45). GyrI in E.coli acts as an antidote to the
plasmid encoded toxin microcin B17 and also involved in
reducing DNA damages from diverse agents (18,46).
Glutamate racemase is the new member of chromosomally
encoded gyrase inhibitors. Like others, it appears to sequester
away DNA gyrase from its site of action. The physiological
basis for MurI-mediated inhibition is not known. Since,
mycobacterial MurI inhibits gyrase in absence of any
peptidoglycan precursor; its expression would have to be
under strict control to avoid any abnormality resulting from
uncontrolled inhibition of gyrase. E.coli MurI is active and
capable of inhibiting DNA gyrase, only upon accumulation
of the peptidoglycan precursor (21). The gyrase inhibitory
YrpC from B.subtilis is also poorly expressed in comparison
to Glr, which is abundantly expressed but has no influence on
DNA gyrase activity (24). When cell wall synthesis and
chromosome segregation go hand in hand during cell divi-
sion, gyrase activity may need to be controlled. The observed
bifunctionality of the glutamate racemase might be a measure
employed by the cell to avoid excess gyrase activity, rather
than inhibiting gyrase in true sense. MurI-mediated modula-
tion might be occurring transiently at the time of cell division
to coordinate the process of cell wall biosynthesis and DNA
replication.
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